APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Immunoglobulin for Intravenous Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Human Immunoglobulin for Intravenous Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025190 pages

Choose your research edition.

Industry ResearchHuman Immunoglobulin for Intravenous Injection Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Immunoglobulin for Intravenous Injection Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Human Immunoglobulin for Intravenous Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Immunoglobulin for Intravenous Injection Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Immunoglobulin for Intravenous Injection Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Human Immunoglobulin for Intravenous Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Human Immunoglobulin for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Immunoglobulin for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Immunoglobulin for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Human Immunoglobulin for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Human Immunoglobulin for Intravenous Injection include Zhenghua Shenghua, Zhongyuan Ruide, Weiguang Biological, Tiantan Biological, Taibang Biological, Yuanda shuyang, Shanghai Laishi, Kangbao Biological and Nanyue Biological, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Immunoglobulin for Intravenous Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Immunoglobulin for Intravenous Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Immunoglobulin for Intravenous Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Immunoglobulin for Intravenous Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Immunoglobulin for Intravenous Injection Segment by Company

Zhenghua Shenghua

Zhongyuan Ruide

Weiguang Biological

Tiantan Biological

Taibang Biological

Yuanda shuyang

Shanghai Laishi

Kangbao Biological

Nanyue Biological

Lvshizi

Hualan Biological

Paisi feike

Boya Biological

Human Immunoglobulin for Intravenous Injection Segment by Type

Children

Adult

Human Immunoglobulin for Intravenous Injection Segment by Application

Treatment

Diagnosis

Disease Prevention

Other

Human Immunoglobulin for Intravenous Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immunoglobulin for Intravenous Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Immunoglobulin for Intravenous Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immunoglobulin for Intravenous Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Immunoglobulin for Intravenous Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Human Immunoglobulin for Intravenous Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Human Immunoglobulin for Intravenous Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Human Immunoglobulin for Intravenous Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Human Immunoglobulin for Intravenous Injection Industry Trends Table 2. Human Immunoglobulin for Intravenous Injection Industry Drivers Table 3. Human Immunoglobulin for Intravenous Injection Industry Opportunities and Challenges Table 4. Human Immunoglobulin for Intravenous Injection Industry Restraints Table 5. Global Human Immunoglobulin for Intravenous Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Human Immunoglobulin for Intravenous Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Human Immunoglobulin for Intravenous Injection Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Manufacturers Table 9. Global Human Immunoglobulin for Intravenous Injection Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Human Immunoglobulin for Intravenous Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Human Immunoglobulin for Intravenous Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Human Immunoglobulin for Intravenous Injection Manufacturers, Product Type & Application Table 13. Global Human Immunoglobulin for Intravenous Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Immunoglobulin for Intravenous Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Children Table 17. Major Manufacturers of Adult Table 18. Global Human Immunoglobulin for Intravenous Injection Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Human Immunoglobulin for Intravenous Injection Sales by Type (2021-2026) & (K Units) Table 20. Global Human Immunoglobulin for Intravenous Injection Sales by Type (2027-2032) & (K Units) Table 21. Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Type (2021-2026) Table 22. Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Type (2027-2032) Table 23. Global Human Immunoglobulin for Intravenous Injection Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Human Immunoglobulin for Intravenous Injection Revenue by Type (2021-2026) & (K Units) Table 25. Global Human Immunoglobulin for Intravenous Injection Revenue by Type (2027-2032) & (K Units) Table 26. Global Human Immunoglobulin for Intravenous Injection Revenue Market Share by Type (2021-2026) Table 27. Global Human Immunoglobulin for Intravenous Injection Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Treatment Table 29. Major Manufacturers of Diagnosis Table 30. Major Manufacturers of Disease Prevention Table 31. Major Manufacturers of Other Table 32. Global Human Immunoglobulin for Intravenous Injection Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Human Immunoglobulin for Intravenous Injection Sales by Application (2021-2026) & (K Units) Table 34. Global Human Immunoglobulin for Intravenous Injection Sales by Application (2027-2032) & (K Units) Table 35. Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Application (2021-2026) Table 36. Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Application (2027-2032) Table 37. Global Human Immunoglobulin for Intravenous Injection Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Human Immunoglobulin for Intravenous Injection Revenue by Application (2021-2026) & (K Units) Table 39. Global Human Immunoglobulin for Intravenous Injection Revenue by Application (2027-2032) & (K Units) Table 40. Global Human Immunoglobulin for Intravenous Injection Revenue Market Share by Application (2021-2026) Table 41. Global Human Immunoglobulin for Intravenous Injection Revenue Market Share by Application (2027-2032) Table 42. Global Human Immunoglobulin for Intravenous Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Human Immunoglobulin for Intravenous Injection Sales by Region (2021-2026) & (K Units) Table 44. Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Region (2021-2026) Table 45. Global Human Immunoglobulin for Intravenous Injection Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Human Immunoglobulin for Intravenous Injection Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Human Immunoglobulin for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Human Immunoglobulin for Intravenous Injection Sales by Country (2021-2026) & (K Units) Table 49. North America Human Immunoglobulin for Intravenous Injection Sales by Country (2027-2032) & (K Units) Table 50. Europe Human Immunoglobulin for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Human Immunoglobulin for Intravenous Injection Sales by Country (2021-2026) & (K Units) Table 52. Europe Human Immunoglobulin for Intravenous Injection Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Human Immunoglobulin for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Human Immunoglobulin for Intravenous Injection Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Human Immunoglobulin for Intravenous Injection Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Human Immunoglobulin for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Human Immunoglobulin for Intravenous Injection Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Human Immunoglobulin for Intravenous Injection Sales by Country (2027-2032) & (K Units) Table 59. Global Human Immunoglobulin for Intravenous Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Human Immunoglobulin for Intravenous Injection Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Human Immunoglobulin for Intravenous Injection Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Human Immunoglobulin for Intravenous Injection Revenue Market Share by Region (2021-2026) Table 63. Global Human Immunoglobulin for Intravenous Injection Revenue Market Share by Region (2027-2032) Table 64. Zhenghua Shenghua Company Information Table 65. Zhenghua Shenghua Business Overview Table 66. Zhenghua Shenghua Human Immunoglobulin for Intravenous Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Zhenghua Shenghua Human Immunoglobulin for Intravenous Injection Product Portfolio Table 68. Zhenghua Shenghua Recent Development Table 69. Zhongyuan Ruide Company Information Table 70. Zhongyuan Ruide Business Overview Table 71. Zhongyuan Ruide Human Immunoglobulin for Intravenous Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Zhongyuan Ruide Human Immunoglobulin for Intravenous Injection Product Portfolio Table 73. Zhongyuan Ruide Recent Development Table 74. Weiguang Biological Company Information Table 75. Weiguang Biological Business Overview Table 76. Weiguang Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Weiguang Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 78. Weiguang Biological Recent Development Table 79. Tiantan Biological Company Information Table 80. Tiantan Biological Business Overview Table 81. Tiantan Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Tiantan Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 83. Tiantan Biological Recent Development Table 84. Taibang Biological Company Information Table 85. Taibang Biological Business Overview Table 86. Taibang Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Taibang Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 88. Taibang Biological Recent Development Table 89. Yuanda shuyang Company Information Table 90. Yuanda shuyang Business Overview Table 91. Yuanda shuyang Human Immunoglobulin for Intravenous Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Yuanda shuyang Human Immunoglobulin for Intravenous Injection Product Portfolio Table 93. Yuanda shuyang Recent Development Table 94. Shanghai Laishi Company Information Table 95. Shanghai Laishi Business Overview Table 96. Shanghai Laishi Human Immunoglobulin for Intravenous Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Shanghai Laishi Human Immunoglobulin for Intravenous Injection Product Portfolio Table 98. Shanghai Laishi Recent Development Table 99. Kangbao Biological Company Information Table 100. Kangbao Biological Business Overview Table 101. Kangbao Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Kangbao Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 103. Kangbao Biological Recent Development Table 104. Nanyue Biological Company Information Table 105. Nanyue Biological Business Overview Table 106. Nanyue Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Nanyue Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 108. Nanyue Biological Recent Development Table 109. Lvshizi Company Information Table 110. Lvshizi Business Overview Table 111. Lvshizi Human Immunoglobulin for Intravenous Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Lvshizi Human Immunoglobulin for Intravenous Injection Product Portfolio Table 113. Lvshizi Recent Development Table 114. Hualan Biological Company Information Table 115. Hualan Biological Business Overview Table 116. Hualan Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Hualan Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 118. Hualan Biological Recent Development Table 119. Paisi feike Company Information Table 120. Paisi feike Business Overview Table 121. Paisi feike Human Immunoglobulin for Intravenous Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Paisi feike Human Immunoglobulin for Intravenous Injection Product Portfolio Table 123. Paisi feike Recent Development Table 124. Boya Biological Company Information Table 125. Boya Biological Business Overview Table 126. Boya Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Boya Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 128. Boya Biological Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Human Immunoglobulin for Intravenous Injection Distributors List Table 132. Human Immunoglobulin for Intravenous Injection Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Human Immunoglobulin for Intravenous Injection Product Image Figure 2. Global Human Immunoglobulin for Intravenous Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Immunoglobulin for Intravenous Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Immunoglobulin for Intravenous Injection Sales (2021-2032) & (K Units) Figure 5. Global Human Immunoglobulin for Intravenous Injection Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Human Immunoglobulin for Intravenous Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Children Image Figure 9. Adult Image Figure 10. Global Human Immunoglobulin for Intravenous Injection Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Human Immunoglobulin for Intravenous Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Type (2021-2032) Figure 13. Global Human Immunoglobulin for Intravenous Injection Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Human Immunoglobulin for Intravenous Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Human Immunoglobulin for Intravenous Injection Revenue Market Share by Type (2021-2032) Figure 16. Treatment Image Figure 17. Diagnosis Image Figure 18. Disease Prevention Image Figure 19. Other Image Figure 20. Global Human Immunoglobulin for Intravenous Injection Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Human Immunoglobulin for Intravenous Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Application (2021-2032) Figure 23. Global Human Immunoglobulin for Intravenous Injection Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Human Immunoglobulin for Intravenous Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Human Immunoglobulin for Intravenous Injection Revenue Market Share by Application (2021-2032) Figure 26. North America Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Human Immunoglobulin for Intravenous Injection Sales Market Share by Country (2021-2032) Figure 28. U.S. Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Human Immunoglobulin for Intravenous Injection Sales Market Share by Country (2021-2032) Figure 33. Germany Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Human Immunoglobulin for Intravenous Injection Sales Market Share by Country (2021-2032) Figure 40. China Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Human Immunoglobulin for Intravenous Injection Sales Market Share by Country (2021-2032) Figure 48. Brazil Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Human Immunoglobulin for Intravenous Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Human Immunoglobulin for Intravenous Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Human Immunoglobulin for Intravenous Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Human Immunoglobulin for Intravenous Injection Revenue (2021-2032) & (US$ Million) Figure 59. North America Human Immunoglobulin for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Human Immunoglobulin for Intravenous Injection Revenue (2021-2032) & (US$ Million) Figure 61. Europe Human Immunoglobulin for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Human Immunoglobulin for Intravenous Injection Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Human Immunoglobulin for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Human Immunoglobulin for Intravenous Injection Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Human Immunoglobulin for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Human Immunoglobulin for Intravenous Injection Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Human Immunoglobulin for Intravenous Injection Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Children
  • Adult
Applications
  • Treatment
  • Diagnosis
  • Disease Prevention
  • Other
Companies covered
  • Zhenghua Shenghua
  • Zhongyuan Ruide
  • Weiguang Biological
  • Tiantan Biological
  • Taibang Biological
  • Yuanda shuyang
  • Shanghai Laishi
  • Kangbao Biological
  • Nanyue Biological
  • Lvshizi
  • Hualan Biological
  • Paisi feike
  • Boya Biological

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Immunoglobulin for Intravenous Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Immunoglobulin for Intravenous Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Human Immunoglobulin for Intravenous Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Human Immunoglobulin for Intravenous Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Human Immunoglobulin for Intravenous Injection Market Dynamics
  1. 2.1 Human Immunoglobulin for Intravenous Injection Industry Trends
  2. 2.2 Human Immunoglobulin for Intravenous Injection Industry Drivers
  3. 2.3 Human Immunoglobulin for Intravenous Injection Industry Opportunities and Challenges
  4. 2.4 Human Immunoglobulin for Intravenous Injection Industry Restraints
3 Human Immunoglobulin for Intravenous Injection Market by Manufacturers
  1. 3.1 Global Human Immunoglobulin for Intravenous Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Human Immunoglobulin for Intravenous Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global Human Immunoglobulin for Intravenous Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Human Immunoglobulin for Intravenous Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Human Immunoglobulin for Intravenous Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Human Immunoglobulin for Intravenous Injection Manufacturers, Product Type & Application
  7. 3.7 Global Human Immunoglobulin for Intravenous Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Human Immunoglobulin for Intravenous Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Human Immunoglobulin for Intravenous Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Human Immunoglobulin for Intravenous Injection Tier 1, Tier 2, and Tier 3
4 Human Immunoglobulin for Intravenous Injection Market by Type
  1. 4.1 Human Immunoglobulin for Intravenous Injection Type Introduction
  2. 4.1.1 Children
  3. 4.1.2 Adult
  4. 4.2 Global Human Immunoglobulin for Intravenous Injection Sales by Type
  5. 4.2.1 Global Human Immunoglobulin for Intravenous Injection Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Human Immunoglobulin for Intravenous Injection Sales by Type (2021-2032)
  7. 4.2.3 Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Type (2021-2032)
  8. 4.3 Global Human Immunoglobulin for Intravenous Injection Revenue by Type
  9. 4.3.1 Global Human Immunoglobulin for Intravenous Injection Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Human Immunoglobulin for Intravenous Injection Revenue by Type (2021-2032)
  11. 4.3.3 Global Human Immunoglobulin for Intravenous Injection Revenue Market Share by Type (2021-2032)
5 Human Immunoglobulin for Intravenous Injection Market by Application
  1. 5.1 Human Immunoglobulin for Intravenous Injection Application Introduction
  2. 5.1.1 Treatment
  3. 5.1.2 Diagnosis
  4. 5.1.3 Disease Prevention
  5. 5.1.4 Other
  6. 5.2 Global Human Immunoglobulin for Intravenous Injection Sales by Application
  7. 5.2.1 Global Human Immunoglobulin for Intravenous Injection Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Human Immunoglobulin for Intravenous Injection Sales by Application (2021-2032)
  9. 5.2.3 Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Application (2021-2032)
  10. 5.3 Global Human Immunoglobulin for Intravenous Injection Revenue by Application
  11. 5.3.1 Global Human Immunoglobulin for Intravenous Injection Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Human Immunoglobulin for Intravenous Injection Revenue by Application (2021-2032)
  13. 5.3.3 Global Human Immunoglobulin for Intravenous Injection Revenue Market Share by Application (2021-2032)
6 Global Human Immunoglobulin for Intravenous Injection Sales by Region
  1. 6.1 Global Human Immunoglobulin for Intravenous Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Immunoglobulin for Intravenous Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Human Immunoglobulin for Intravenous Injection Sales by Region (2021-2026)
  4. 6.2.2 Global Human Immunoglobulin for Intravenous Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Immunoglobulin for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Human Immunoglobulin for Intravenous Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Human Immunoglobulin for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Human Immunoglobulin for Intravenous Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Human Immunoglobulin for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Human Immunoglobulin for Intravenous Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Human Immunoglobulin for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Human Immunoglobulin for Intravenous Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Human Immunoglobulin for Intravenous Injection Revenue by Region
  1. 7.1 Global Human Immunoglobulin for Intravenous Injection Revenue by Region
  2. 7.1.1 Global Human Immunoglobulin for Intravenous Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Human Immunoglobulin for Intravenous Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global Human Immunoglobulin for Intravenous Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global Human Immunoglobulin for Intravenous Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Human Immunoglobulin for Intravenous Injection Revenue (2021-2032)
  8. 7.2.2 North America Human Immunoglobulin for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Human Immunoglobulin for Intravenous Injection Revenue (2021-2032)
  11. 7.3.2 Europe Human Immunoglobulin for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Human Immunoglobulin for Intravenous Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Human Immunoglobulin for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Human Immunoglobulin for Intravenous Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Human Immunoglobulin for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhenghua Shenghua
  2. 8.1.1 Zhenghua Shenghua Company Information
  3. 8.1.2 Zhenghua Shenghua Business Overview
  4. 8.1.3 Zhenghua Shenghua Human Immunoglobulin for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zhenghua Shenghua Human Immunoglobulin for Intravenous Injection Product Portfolio
  6. 8.1.5 Zhenghua Shenghua Recent Developments
  7. 8.2 Zhongyuan Ruide
  8. 8.2.1 Zhongyuan Ruide Company Information
  9. 8.2.2 Zhongyuan Ruide Business Overview
  10. 8.2.3 Zhongyuan Ruide Human Immunoglobulin for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zhongyuan Ruide Human Immunoglobulin for Intravenous Injection Product Portfolio
  12. 8.2.5 Zhongyuan Ruide Recent Developments
  13. 8.3 Weiguang Biological
  14. 8.3.1 Weiguang Biological Company Information
  15. 8.3.2 Weiguang Biological Business Overview
  16. 8.3.3 Weiguang Biological Human Immunoglobulin for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Weiguang Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  18. 8.3.5 Weiguang Biological Recent Developments
  19. 8.4 Tiantan Biological
  20. 8.4.1 Tiantan Biological Company Information
  21. 8.4.2 Tiantan Biological Business Overview
  22. 8.4.3 Tiantan Biological Human Immunoglobulin for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Tiantan Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  24. 8.4.5 Tiantan Biological Recent Developments
  25. 8.5 Taibang Biological
  26. 8.5.1 Taibang Biological Company Information
  27. 8.5.2 Taibang Biological Business Overview
  28. 8.5.3 Taibang Biological Human Immunoglobulin for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Taibang Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  30. 8.5.5 Taibang Biological Recent Developments
  31. 8.6 Yuanda shuyang
  32. 8.6.1 Yuanda shuyang Company Information
  33. 8.6.2 Yuanda shuyang Business Overview
  34. 8.6.3 Yuanda shuyang Human Immunoglobulin for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Yuanda shuyang Human Immunoglobulin for Intravenous Injection Product Portfolio
  36. 8.6.5 Yuanda shuyang Recent Developments
  37. 8.7 Shanghai Laishi
  38. 8.7.1 Shanghai Laishi Company Information
  39. 8.7.2 Shanghai Laishi Business Overview
  40. 8.7.3 Shanghai Laishi Human Immunoglobulin for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Shanghai Laishi Human Immunoglobulin for Intravenous Injection Product Portfolio
  42. 8.7.5 Shanghai Laishi Recent Developments
  43. 8.8 Kangbao Biological
  44. 8.8.1 Kangbao Biological Company Information
  45. 8.8.2 Kangbao Biological Business Overview
  46. 8.8.3 Kangbao Biological Human Immunoglobulin for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kangbao Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  48. 8.8.5 Kangbao Biological Recent Developments
  49. 8.9 Nanyue Biological
  50. 8.9.1 Nanyue Biological Company Information
  51. 8.9.2 Nanyue Biological Business Overview
  52. 8.9.3 Nanyue Biological Human Immunoglobulin for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Nanyue Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  54. 8.9.5 Nanyue Biological Recent Developments
  55. 8.10 Lvshizi
  56. 8.10.1 Lvshizi Company Information
  57. 8.10.2 Lvshizi Business Overview
  58. 8.10.3 Lvshizi Human Immunoglobulin for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lvshizi Human Immunoglobulin for Intravenous Injection Product Portfolio
  60. 8.10.5 Lvshizi Recent Developments
  61. 8.11 Hualan Biological
  62. 8.11.1 Hualan Biological Company Information
  63. 8.11.2 Hualan Biological Business Overview
  64. 8.11.3 Hualan Biological Human Immunoglobulin for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hualan Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  66. 8.11.5 Hualan Biological Recent Developments
  67. 8.12 Paisi feike
  68. 8.12.1 Paisi feike Company Information
  69. 8.12.2 Paisi feike Business Overview
  70. 8.12.3 Paisi feike Human Immunoglobulin for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Paisi feike Human Immunoglobulin for Intravenous Injection Product Portfolio
  72. 8.12.5 Paisi feike Recent Developments
  73. 8.13 Boya Biological
  74. 8.13.1 Boya Biological Company Information
  75. 8.13.2 Boya Biological Business Overview
  76. 8.13.3 Boya Biological Human Immunoglobulin for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Boya Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  78. 8.13.5 Boya Biological Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Immunoglobulin for Intravenous Injection Value Chain Analysis
  2. 9.1.1 Human Immunoglobulin for Intravenous Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Immunoglobulin for Intravenous Injection Production Mode & Process
  6. 9.2 Human Immunoglobulin for Intravenous Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Immunoglobulin for Intravenous Injection Distributors
  9. 9.2.3 Human Immunoglobulin for Intravenous Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst